1173524-20-3Relevant academic research and scientific papers
Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity
-
Page/Page column 4; 12, (2010/03/02)
The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists
Hartz, Richard A.,Ahuja, Vijay T.,Arvanitis, Argyrios G.,Rafalski, Maria,Yue, Eddy W.,Denhart, Derek J.,Schmitz, William D.,Ditta, Jonathan L.,Deskus, Jeffrey A.,Brenner, Allison B.,Hobbs, Frank W.,Payne, Joseph,Lelas, Snjezana,Li, Yu-Wen,Molski, Thaddeus F.,Mattson, Gail K.,Peng, Yong,Wong, Harvey,Grace, James E.,Lentz, Kimberley A.,Qian-Cutrone, Jingfang,Zhuo, Xiaoliang,Shu, Yue-Zhong,Lodge, Nicholas J.,Zaczek, Robert,Combs, Andrew P.,Olson, Richard E.,Bronson, Joanne J.,Mattson, Ronald J.,Macor, John E.
experimental part, p. 4173 - 4191 (2010/02/17)
Evidence suggests that corticotropin-releasing factor-1 (CRF1) receptor antagonistsmay offer therapeutic potential for the treatment of diseases associated with elevated levels of CRF such as anxiety and depression. A pyrazinone-based chemotype
